Olaparib (AZD2281)

For research use only.

Catalog No.S1060 Synonyms: Ku-0059436

586 publications

Olaparib (AZD2281) Chemical Structure

CAS No. 763113-22-0

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Olaparib (AZD2281) has been cited by 586 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NWWxcWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPTOEBl NFn6TnVKSzVyPUWuO|A2KCEQvF2g NUfFc5hTOTh3NUm2NVM>
KP6.3 NWW3UXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWS0JIQ> Mn\mTWM2OD1zMD60Nlgh|ryPIB?= NEXQWo8yQDV3OU[xNy=>
KP7.7 NYL5OHd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:0JIQ> M3LPdGlEPTB;NUegcm0h NHuxO3AyQDV3OU[xNy=>
KB2P3.4 NYjoc5FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[0JIQ> NFfuOYpKSzVyPUGyOEBOKA>? NV;1c4V3OTh3NUm2NVM>
KB2P1.21 M3v6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHkOEBl MmHMTWM2OD16OUC3JI5OKA>? NV21Um14OTh3NUm2NVM>
U373-MG Mn3qR5l1d3SxeHnjJGF{e2G7 MVexJO69VSB? NVe0TYpDOjRiaB?= NV;FXZRzUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= NYLDUo1ROTh7NUS3NVI>
T98G MoDYR5l1d3SxeHnjJGF{e2G7 NFPFenkyKM7:TTC= NV;GbG1kOjRiaB?= Mkm4TY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NEnGfXEyQDl3NEexNi=>
U87-MG NEnqVHVEgXSxdH;4bYMhSXO|YYm= MUGxJO69VSB? NHP0cHUzPCCq NXXnSZJxUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= MVyxPFk2PDdzMh?=
UVW NInrfZZEgXSxdH;4bYMhSXO|YYm= MY[1NFAhdk1? MViyOEBp MkC4TY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NWDYWGlTOTh7NUS3NVI>
HeLa NUH5ZWpWTnWwY4Tpc44hSXO|YYm= MU[1NFAhdk1? NYjR[YlUPCCq NI\sUZRE[XW|ZYOgZUBud2Snc4Sg[IVt[XliaX6gdoVrd2mwaX7nJI9nKHKjZHnheIlwdi2rbnT1Z4VlKESQQTDidoVic3N? NWrMWpA4OTh7NUS3NVI>
HeLa MVTGeY5kfGmxbjDBd5NigQ>? MV:xJO69VSB? NET0clYzPCCq NW\iUYU4TW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S= NXP5UZRzOTh7NUS3NVI>
T98G M{T2NmZ2dmO2aX;uJGF{e2G7 M{f3WlEh|ryPIB?= MYeyOEBp NYnadmFqTW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S= Mnn2NVg6PTR5MUK=
L3 MUHDfZRwfG:6aXOgRZN{[Xl? M{DMdFUh|ryPIB?= M4HIVVk3KGh? NGeySoxFVVOR M2fB[nNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> MXKyNFEzPDR3OR?=
Granta-519 NIjKT29EgXSxdH;4bYMhSXO|YYm= MUi1JO69VSB? NXvMeFBMQTZiaB?= NHTG[lFFVVOR M4XiTXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? MVeyNFEzPDR3OR?=
BT NVHneYJqS3m2b4TvfIlkKEG|c3H5 MmX1OUDPxE1i NGf1TG46PiCq M{[xZmROW09? Mo\xV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NYLBNXJIOjBzMkS0OVk>
UPN2 M3;IbGN6fG:2b4jpZ{BCe3OjeR?= M3T4RVUh|ryPIB?= NU\Ie3BZQTZiaB?= MVPEUXNQ M3\Z[3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? MUOyNFEzPDR3OR?=
HBL-2 NWLV[o5LS3m2b4TvfIlkKEG|c3H5 NX3veFAzPSEQvF2g M3\m[|k3KGh? MYHEUXNQ NIHqNpdUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NEL4PXozODF{NES1PS=>
JVM-2 MXnDfZRwfG:6aXOgRZN{[Xl? NFzadWU2KM7:TTC= Mke2PVYhcA>? NXG1VWlMTE2VTx?= NHHk[WdUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NXLUN|JkOjBzMkS0OVk>
Z138 NWLpU3VuS3m2b4TvfIlkKEG|c3H5 NGnPRnk2KM7:TTC= M4PKUFk3KGh? MnK3SG1UVw>? NFW3dHRUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MViyNFEzPDR3OR?=
RWPE MlLJTY53[XOrdnWgRZN{[Xl? NYO4[W93OjVizszN M2HVO|Q5KGh? MmrySG1UVw>? NXzlW4U6W2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? M{nMUVIyPTd3OE[1
VCaP MnLrTY53[XOrdnWgRZN{[Xl? NEXqd5YzPSEQvF2= Mln1OFghcA>? M1PRWGROW09? NHTwV21UcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v NFHOeJgzOTV5NUi2OS=>
Mouse H2AX−/− ES Cells NI[1XItEgXSxdH;4bYMhSXO|YYm= M4LEVlIvPSEQvF2= MmXnNlAhcA>? MmPPV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NWDhZWE6OjN|NUW0PFk>
Mouse ATM−/− ES Cells NHL3UXVEgXSxdH;4bYMhSXO|YYm= MnnkNk42KM7:TR?= MnnZNlAhcA>? MmTwV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs MVKyN|M2PTR6OR?=
H1650 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjzXZAzOCEQvF2= MmPzNVQ1KGh? MmLSTWM2OD1zNT60O{DPxE1? NGmwWnQzOzJ|OUiwPS=>
H1650PTEN+ MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLJNlAh|ryP NV3RTGFoOTR2IHi= MkX5TWM2OD13MD64N{DPxE1? NE\TW5AzOzJ|OUiwPS=>
PC-9 Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH2NlAh|ryP MYSxOFQhcA>? MWnJR|UxRTVwOEig{txO MmH5NlMzOzl6MEm=
PC-9PTEN− NHmxNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKyNEDPxE1? Mke3NVQ1KGh? NVPJZo5qUUN3ME22MlUzKM7:TR?= NUDTTFlCOjN{M{m4NFk>
MDA-MB-231 M3TMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[1R|RRPSCmYYm= M3:3VGlEPTB;Nj65JO69VQ>? M3ruc|I{PzZyNEm2
MDA-MB-468 M4TNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHtT2Y{PSCmYYm= NF3hbppKSzVyPUWuNEDPxE1? NWTKcWI{OjN5NkC0PVY>
BT20 M4W5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf3OUBl[Xl? M3LKN2lEPTB;Nz63JO69VQ>? MmHsNlM4PjB2OU[=
HCC1143 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7r[FBUPSCmYYm= Mn;vTWM2OD1zMT6xJO69VQ>? NFX0bZAzOzd4MES5Oi=>
HCC1937 M1X2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXkWXE2KGSjeR?= MYPJR|UxRTF{Lk[g{txO MlrGNlM4PjB2OU[=
Hs578t MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH1NJQ2KGSjeR?= MnrwTWM2OD13Lk[g{txO MlXMNlM4PjB2OU[=
Hs578t(si) NWK0bnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL1OUBl[Xl? NUj4cYFoUUN3ME23MlUh|ryP M1jlblI{PzZyNEm2
BT474 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW1JIRigQ>? M1LBZmlEPTB;MUmuPEDPxE1? MUKyN|c3ODR7Nh?=
JIMT1 NHj3cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\aWFUh\GG7 NYPGUFZUUUN3ME23Mlch|ryP MoPCNlM4PjB2OU[=
SKBR3 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC3W|M2KGSjeR?= NIL2U5NKSzVyPUGxMlEh|ryP MnriNlM4PjB2OU[=
SUM159 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf2OUBl[Xl? NHvxN2xKSzVyPUSuNkDPxE1? M{m1OlI{PzZyNEm2
CAMA1 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLJRYlPPSCmYYm= NWfi[VVZUUN3ME2xOU45KM7:TR?= NHLGelIzOzd4MES5Oi=>
MCF7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq1JIRigQ>? MUjJR|UxRTVwODFOwG0> MWmyN|c3ODR7Nh?=
T47D M2HhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi1JIRigQ>? MUPJR|UxRTlwNjFOwG0> MoixNlM4PjB2OU[=
HCT116 M2Hv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNFAh|ryP NIe5T4U1QCCq NFflboZFVVOR Mor3TWM2OD1{LkWg{txOKA>? MX:yOFU4Pzl2MR?=
SW1116 NH\wWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrjNVAxKM7:TR?= NIq0UYs1QCCq MYHEUXNQ MmDUTWM2OD1zMECg{txO MkDqNlQ2Pzd7NEG=
HT29 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jGUFExOCEQvF2= MnfhOFghcA>? M2jwU2ROW09? NUTtVllkUUN3ME2xOE44KM7:TR?= NIrjTlAzPDV5N{m0NS=>
LoVo MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWxNFAh|ryP Mn7aOFghcA>? NEDOWlJFVVOR MWTJR|UxRTF|LkSg{txO M1HmPFI1PTd5OUSx
HCT-15 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vWWlExOCEQvF2= NYGzPHVkPDhiaB?= NGPoZnRFVVOR M{XZd2lEPTB;MUCg{txO MmjyNlQ2Pzd7NEG=
SW48 M2Lmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;VdYRCOTByIN88US=> MVO0PEBp NXu5bG8{TE2VTx?= MnTZTWM2OD17LkWg{txO M17tTlI1PTd5OUSx
C-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\tN5duOTByIN88US=> Mn;IOFghcA>? NVe0TppVTE2VTx?= NVfQTlRlUUN3ME23MlYh|ryP NXzKR2VUOjR3N{e5OFE>
RKO NFP1OYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLyNVAxKM7:TR?= M{LU[VQ5KGh? NYXKXZFRTE2VTx?= NIH3WFBKSzVyPUWuPUDPxE1? Mnu0NlQ2Pzd7NEG=
HCT116 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC5O|ByOTByIN88US=> NYDOPVFnPDhiaB?= NUH3PZRoTE2VTx?= NUXpR5Y6WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MYWyOFU4Pzl2MR?=
SW1116 M4fKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLDNVAxKM7:TR?= M{K1PVQ5KGh? NHi1cIxFVVOR MnLYVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MlTMNlQ2Pzd7NEG=
HT29 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XSOlExOCEQvF2= MWm0PEBp MVrEUXNQ NVfWfot3WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= M1\TR|I1PTd5OUSx
LoVo NImxbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxNFAh|ryP NXfJcW95PDhiaB?= NXrzUYN7TE2VTx?= M2fMO3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MlWxNlQ2Pzd7NEG=
SW48 NHrhU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPC[ZRROTByIN88US=> M1G2clQ5KGh? NIj3[oVFVVOR Mlz2VI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? M4rYVFI1PTd5OUSx
C-1 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHDeVcyODBizszN NHjUc5M1QCCq MnLhSG1UVw>? MYDQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh Mnn3NlQ2Pzd7NEG=
RKO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jOVFExOCEQvF2= M4G4WFQ5KGh? NXvxfWtLTE2VTx?= NHPYT4RRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MWKyOFU4Pzl2MR?=
HCT116 NXPPZnZtTnWwY4Tpc44hSXO|YYm= M{GzWFExKG6P MnjtNVIhcA>? MlOzSG1UVw>? NXi4[mNCUW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 NUPRU|Q3OjR3N{e5OFE>
HT29 MXXGeY5kfGmxbjDBd5NigQ>? NYjmcJZHOTBibl2= Mnn5NVIhcA>? NWC5R5JpTE2VTx?= NGPvSXJKdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= MWOyOFU4Pzl2MR?=
TE-6 M1fafWZ2dmO2aX;uJGF{e2G7 MY[1JO69VSB? MnnENVIhcA>? M3fCeWROW09? MnzMTY5lfWOnczDHNk9OKGG{cnXzeC=> NYfuU3k5OjR{MUmxOlQ>
TE-6 MV;GeY5kfGmxbjDBd5NigQ>? MUC1JO69VSB? MWiyOEBp NXjHT4JxTE2VTx?= MXLJcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq Ml7uNlQzOTlzNkS=
Hep3B MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PkS|QxKM7:TTC= MkHFO|IhcA>? NE\JS|FFVVOR MVPTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=> MXiyOVA4Ojd3Mh?=
Huh7 NUnNb3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[0NEDPxE1i M2HnOVczKGh? MUHEUXNQ M3XkZnN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS MmPNNlUxPzJ5NUK=
Hep3B MYTGeY5kfGmxbjDBd5NigQ>? NID3U3E1OCEQvF2g M2nN[VI1KGh? MlS2SG1UVw>? MljlTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT M1P1dFI2ODd{N{Wy
Huh7 NFS4[HJHfW6ldHnvckBCe3OjeR?= Mn7lOFAh|ryPIB?= MWGyOEBp NUP1VFJWTE2VTx?= M3XXZWlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= M4ixd|I2ODd{N{Wy
Hep3B NFHHVJFHfW6ldHnvckBCe3OjeR?= NUPyW|FZPDBizszNJC=> NFG4[3ozPCCq M4\iTGROW09? MkW2TY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT NELTW3AzPTB5Mke1Ni=>
Huh7 NGC1eJZHfW6ldHnvckBCe3OjeR?= NEnIcIg1OCEQvF2g NGjLd2MzPCCq M1LnSWROW09? NUPoRpZJUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR NGTH[JozPTB5Mke1Ni=>
SGC-7901 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXiN|DDqM7:TR?= M2exWVQ5KGh? M3j6UmROW09? Mlm3Roxw[2tib4jhcIlxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo MmixNlU4PjdyN{[=
COLO-800 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHmTWM2OD1yLkS0NVY1KM7:TR?= MkL3V2FPT0WU
EoL-1- NFXuPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXUdZdKSzVyPUCuOVY1PDZizszN M4Xq[3NCVkeHUh?=
NCI-H209 M2jiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHniR2JKSzVyPUCuPVE2PTZizszN NWXifVNwW0GQR1XS
ES1 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLYTWM2OD1zLkGxOFA5KM7:TR?= MUHTRW5ITVJ?
NKM-1 M4TiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnQbGpWUUN3ME2xMlI2OzR5IN88US=> NFLpXIpUSU6JRWK=
NTERA-S-cl-D1 NVzYcFZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj5V3l{UUN3ME2xMlM{OzRzIN88US=> NV3jT|VPW0GQR1XS
MHH-ES-1 M1;uemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwNkKwOlch|ryP M2rySXNCVkeHUh?=
ES8 M{PyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz5TWM2OD1zLkeyOFE1KM7:TR?= NVf1Z5Y{W0GQR1XS
NCI-H720 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WwbWlEPTB;Mj6yNFY6QSEQvF2= M1T3SXNCVkeHUh?=
EW-3 NUDnXJZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfzUGpKSzVyPUKuNlc2OzRizszN NHTVVmZUSU6JRWK=
D-566MG M3izUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jXcGlEPTB;Mj60OFU3QCEQvF2= MXHTRW5ITVJ?
697 NFPGZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwOESxO|Mh|ryP M33BXnNCVkeHUh?=
ES5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX71UpRrUUN3ME2yMlg5OTh7IN88US=> MV\TRW5ITVJ?
COLO-684 NWLrSohQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nDTGlEPTB;Mz61NVY6PiEQvF2= NXvIZ|JwW0GQR1XS
ML-2 M1PqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLXS2xKUUN3ME2zMlYxODV6IN88US=> MWrTRW5ITVJ?
MC-IXC NEn5R2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPUTWM2OD1|Lk[zN|k{KM7:TR?= M13yZXNCVkeHUh?=
DB MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNwNkW0OFgh|ryP NHn6T3FUSU6JRWK=
HCC2218 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fVV2lEPTB;Mz63N|ExOyEQvF2= MYfTRW5ITVJ?
NCI-H510A NUO5TWJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTnNmpKSzVyPUOuPFI4OjRizszN NXzSfZhCW0GQR1XS
NCI-H526 NYfSPXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fmNGlEPTB;Mz64Olk2QCEQvF2= NXLtNoJQW0GQR1XS
MV-4-11 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Je4tKSzVyPUSuNVM{OzRizszN NWLZSJR2W0GQR1XS
PA-1 NVHpVlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTRwMkWyPUDPxE1? NVHWPWpzW0GQR1XS
EW-22 NIHDb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwM{W4OkDPxE1? M{f1fXNCVkeHUh?=
KASUMI-1 NX[0dGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H3d2lEPTB;ND60NFExQSEQvF2= NILteYVUSU6JRWK=
LU-139 NYLNbZc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHB[XFLUUN3ME20Mlc2QDJ7IN88US=> MWDTRW5ITVJ?
SBC-1 NHzp[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j1SGlEPTB;ND64NFkxQCEQvF2= NE[yd|ZUSU6JRWK=
H4 NVzTTXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnJU4NKSzVyPUSuPFk1PDNizszN NXj6T4xYW0GQR1XS
EW-11 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVwMEiwO|Ih|ryP NWq0NVdLW0GQR1XS
NBsusSR NHnvXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTVwMUKwOVUh|ryP MoTXV2FPT0WU
RPMI-8226 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVwMUWyOFQh|ryP MmDxV2FPT0WU
DEL M{LnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;wTWM2OD13LkKwNFA3KM7:TR?= NV:xdm84W0GQR1XS
ES4 NVe2XoY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTVwNUGzPFkh|ryP NWfCd3VpW0GQR1XS
GCT MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PFXmlEPTB;NT61Olg2PiEQvF2= MYjTRW5ITVJ?
NCI-H1048 M1PEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVwOUeyO|Mh|ryP NHPLd|ZUSU6JRWK=
NCI-SNU-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTZwMEKyJO69VQ>? M2LmXnNCVkeHUh?=
ES7 NWjZOIdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECw[JhKSzVyPU[uNFM2PzdizszN MXPTRW5ITVJ?
SW982 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTZwMEmxN|ch|ryP NXTkdI4{W0GQR1XS
L-363 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3JSWtKSzVyPU[uN|M6PzRizszN NX;VRYlmW0GQR1XS
HT-1080 NHq2Z4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\kO|JKSzVyPU[uOFk3QDNizszN MnjrV2FPT0WU
HAL-01 NXXNXXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXkWnFKSzVyPU[uOVExQSEQvF2= MX;TRW5ITVJ?
NB14 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy4W|dKUUN3ME22MlY1ODN7IN88US=> M4\ycHNCVkeHUh?=
EW-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\JRWlEPTB;Nj63O|QzPCEQvF2= NV\0[VRyW0GQR1XS
NY NGnVelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfPfWtsUUN3ME22Mlk1PjB3IN88US=> MoXaV2FPT0WU
NCI-SNU-5 NESxb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDafJBKSzVyPUeuNVA1OzNizszN NEHNVJdUSU6JRWK=
MS-1 NIewO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTdwMUe0PVQh|ryP M4\Z[3NCVkeHUh?=
EW-16 M{jLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfGWGJjUUN3ME23MlMyQDZzIN88US=> NYPCUVJVW0GQR1XS
LU-65 NHrSWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm0eJF7UUN3ME23MlQ5PDF5IN88US=> NFXpUnZUSU6JRWK=
HGC-27 NGn6emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTdwN{KxO|Mh|ryP MonIV2FPT0WU
CTB-1 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLHPXBKSzVyPUeuO|YyPzVizszN MWrTRW5ITVJ?
5637 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnmTWM2OD15LkmyPFYh|ryP NGO3dIdUSU6JRWK=
U251 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEftU|FKSzVyPUeuPVQxOTZizszN M{fn[3NCVkeHUh?=
HOS NF2yT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\MPYRKSzVyPUiuNlMxODdizszN M2qxeXNCVkeHUh?=
DOHH-2 NIriUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\aTWM2OD16LkKzOVgh|ryP MnfnV2FPT0WU
EW-1 M{HkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjXT5BKSzVyPUiuN|AxQDhizszN NYXGfZRFW0GQR1XS
BV-173 M2Xle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPRTWM2OD16LkW1OVQh|ryP Ml\IV2FPT0WU
8-MG-BA M4jUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHyXXFGUUN3ME24MlY5QTh6IN88US=> MVjTRW5ITVJ?
NB69 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3pPWFKSzVyPUiuO|A6OjFizszN MXzTRW5ITVJ?
NCI-H69 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTlwOUC5OlEh|ryP MWnTRW5ITVJ?
RS4-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFzLkKyNFgh|ryP NHzTd5lUSU6JRWK=
ONS-76 M1rqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjWU25PUUN3ME2xNU4zQTR5IN88US=> NFK5VlZUSU6JRWK=
SF539 M3PjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLmWJZKSzVyPUGxMlQ5QDlizszN M1:5bHNCVkeHUh?=
HuO-3N1 NYnoVldWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKxZ49KSzVyPUGxMlU4QTZizszN M2PmV3NCVkeHUh?=
NCI-H1651 NGXnc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLyTWM2OD1zMj6zNVE2KM7:TR?= NEW4[HRUSU6JRWK=
KARPAS-45 M2HmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF{LkO3OkDPxE1? M170XHNCVkeHUh?=
SK-NEP-1 M1P3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12zb2lEPTB;MUKuOFYxQSEQvF2= MnToV2FPT0WU
LAMA-84 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzaOVdKSzVyPUGzMlExQTVizszN NFjxSHdUSU6JRWK=
NCI-H1155 M1jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF|LkK4OVYh|ryP Mor2V2FPT0WU
CTV-1 NYrWWnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLm[nlUUUN3ME2xN{41PDVizszN Mo[wV2FPT0WU
QIMR-WIL M2PrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPQcFJKSzVyPUGzMlc5OTRizszN M13WSHNCVkeHUh?=
H9 NIjrWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF|Lki0O|Uh|ryP MUfTRW5ITVJ?
SK-MEL-1 NI\4ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rYNWlEPTB;MUOuPVM1PyEQvF2= NH2zTnNUSU6JRWK=
HD-MY-Z MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF2LkC2N|ch|ryP NEfKPJZUSU6JRWK=
TI-73 NYiyVVI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF2LkKzOVYh|ryP M2XGV3NCVkeHUh?=
JVM-3 NV;xNohCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzob|lZUUN3ME2xOU42PzF4IN88US=> NVXQd5F4W0GQR1XS
D-247MG Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF3LkW5N{DPxE1? NYi2cXE3W0GQR1XS
VA-ES-BJ M3fWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\HSmRoUUN3ME2xOU43ODl5IN88US=> MWPTRW5ITVJ?
NOS-1 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLPTWM2OD1zNT62OVIzKM7:TR?= MYLTRW5ITVJ?
MOLT-4 NXHrTJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPaTWM2OD1zNj63OVIh|ryP NF;JRYlUSU6JRWK=
Mo-T NIjIT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF5LkC4OFkh|ryP NHqxbYdUSU6JRWK=
NCI-H1770 NIGwO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljVTWM2OD1zNz6xOVQ{KM7:TR?= M1znXnNCVkeHUh?=
COLO-320-HSR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF5LkG4Nlch|ryP NIXuNHBUSU6JRWK=
TE-12 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF5LkewOVQh|ryP MVHTRW5ITVJ?
NCI-H82 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXCSGdKSzVyPUG3Mlg4OjhizszN MYrTRW5ITVJ?
NEC8 NVLEPWxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HxcmlEPTB;MUiuNVMyPiEQvF2= MXjTRW5ITVJ?
HSC-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rTSGlEPTB;MUiuO|QyPCEQvF2= MVPTRW5ITVJ?
NCI-H1092 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[0XWRKSzVyPUG4Mlc2QTVizszN M1rTfHNCVkeHUh?=
NCI-H292 NWDPRYRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH32WYxKSzVyPUG5MlA1QDlizszN MXPTRW5ITVJ?
L-428 NGHRdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TPRWlEPTB;MUmuOVU6KM7:TR?= NGi0dnVUSU6JRWK=
LU-134-A NYXkSoo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWxTWM2OD1zOT61O|Ih|ryP NEj4bFRUSU6JRWK=
GI-ME-N NXryRYQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF7LkW3OFch|ryP MU\TRW5ITVJ?
ALL-PO MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXaVIVGUUN3ME2xPU42QTd{IN88US=> MYHTRW5ITVJ?
D-283MED MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;LWnpKSzVyPUG5MlkyPSEQvF2= NHfOUVhUSU6JRWK=
D-423MG M1foemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj2d4hKSzVyPUG5Mlk6PjdizszN NWnaV3MzW0GQR1XS
CAKI-1 NU\jdWRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP5TWM2OD1{MD6yNlE6KM7:TR?= NHnyZ4hUSU6JRWK=
ETK-1 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof5TWM2OD1{MD6yOlE2KM7:TR?= NUXj[2MzW0GQR1XS
G-402 M1XhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjjSWxlUUN3ME2yNE42OzN2IN88US=> NHHzV4VUSU6JRWK=
HL-60 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf2TWM2OD1{MT6xOlE{KM7:TR?= MUfTRW5ITVJ?
A2058 NVnxNFZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknLTWM2OD1{MT60OFc4KM7:TR?= MVXTRW5ITVJ?
CHP-212 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPMRVhlUUN3ME2yNU46ODVzIN88US=> MX;TRW5ITVJ?
KY821 M4PUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TkUmlEPTB;MkGuPVc2KM7:TR?= NWnrcXZmW0GQR1XS
TYK-nu NWTv[oI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXPOnc1UUN3ME2yNk4xPjVzIN88US=> MXzTRW5ITVJ?
JVM-2 NG\ST5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfwW3hsUUN3ME2yNk4zQTh|IN88US=> NFnSVI5USU6JRWK=
KU812 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvPbW1IUUN3ME2yNk44OzF{IN88US=> MX7TRW5ITVJ?
MKN28 NVjjUVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn22TWM2OD1{Mj65NFE2KM7:TR?= MUDTRW5ITVJ?
ECC10 NFPzWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPBTWM2OD1{Mz63OFEh|ryP M2HBTHNCVkeHUh?=
BHT-101 NWXWfWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ2LkCwNFgh|ryP NGf1XW9USU6JRWK=
DU-4475 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ2LkOzN|ch|ryP MUjTRW5ITVJ?
769-P NEDGPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vDRWlEPTB;MkSuPFQ3PiEQvF2= NXfESXdmW0GQR1XS
HEC-1 NI\MUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ3LkS0OUDPxE1? MWnTRW5ITVJ?
MOLT-13 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ3LkWzN|Eh|ryP Mmn1V2FPT0WU
8505C NEXmXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly3TWM2OD1{Nj60PVc4KM7:TR?= NHfhNZpUSU6JRWK=
GB-1 NUKyUVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ4LkexO|Yh|ryP NFrWPG1USU6JRWK=
SF126 NVnTU29YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnNU5RYUUN3ME2yOk44PjR6IN88US=> MkXsV2FPT0WU
A4-Fuk MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPxZmhKSzVyPUK3MlEzPzFizszN MoXYV2FPT0WU
OVCAR-8 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTlZoptUUN3ME2yO{4yPTN7IN88US=> M1z1NnNCVkeHUh?=
NCI-H1304 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrYTWM2OD1{Nz61OEDPxE1? MlzlV2FPT0WU
GR-ST Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXJNohKSzVyPUK4MlA1PyEQvF2= NEPmN29USU6JRWK=
G-401 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrGTWM2OD1{OD61NFk3KM7:TR?= M1zqd3NCVkeHUh?=
LXF-289 NFXiNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PDNGlEPTB;MkiuOVY2OSEQvF2= NXqydXllW0GQR1XS
DBTRG-05MG M4riOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr5bG5pUUN3ME2yPE46OjB2IN88US=> M2TjNHNCVkeHUh?=
YKG-1 MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq2TWM2OD1{OT64Olgh|ryP MYPTRW5ITVJ?
GAMG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ7Lkm5N{DPxE1? NELodFhUSU6JRWK=
HCT-116 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNyLkC1OFgh|ryP NGfuS4FUSU6JRWK=
S-117 NH7tPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTQeYhjUUN3ME2zNU4zOjV5IN88US=> MkLMV2FPT0WU
NCI-H1693 NWTxR3lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aTWM2OD1|Mz62OVQzKM7:TR?= NW\0ZYw1W0GQR1XS
A427 M1iyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTN|Lkm5O|Yh|ryP M2C5bXNCVkeHUh?=
HT-29 NYnVZXVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN2Lk[wN|Ih|ryP NGTPfmRUSU6JRWK=
P12-ICHIKAWA NFzXW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN2Lke0PVEh|ryP MYDTRW5ITVJ?
CAL-51 NXnrXIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN3LkC3NFkh|ryP M3rV[3NCVkeHUh?=
Ramos-2G6-4C10 NEHmbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHKTodKSzVyPUO1MlI1OjVizszN NHi1dIJUSU6JRWK=
SCH MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHEWI16UUN3ME2zOk41OTd2IN88US=> NHHUV4RUSU6JRWK=
SK-MEL-24 NHjZcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny0TWM2OD1|Nj65NFQ1KM7:TR?= M3joeXNCVkeHUh?=
SW1573 NXi5VIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHJW2RKSzVyPUO4MlczOTZizszN MV3TRW5ITVJ?
BALL-1 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN7LkKxNlkh|ryP NEfVXYNUSU6JRWK=
BE-13 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\5TWM2OD1|OT6zNlkh|ryP M4jPVHNCVkeHUh?=
GI-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxd4hCUUN3ME2zPU45PjR5IN88US=> Mk\UV2FPT0WU
GOTO NXLYWJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrmcoNKSzVyPUO5MlkyOzlizszN MU\TRW5ITVJ?
A673 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnsO|U4UUN3ME20NU4xOzR|IN88US=> NXTIW4V1W0GQR1XS
KG-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17VeGlEPTB;NEOuN|k1KM7:TR?= NGm3c2dUSU6JRWK=
GP5d NIXWUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR2LkC2OlYh|ryP M2fGeHNCVkeHUh?=
MFM-223 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjkNo1KSzVyPUS0MlEzOjhizszN MmXmV2FPT0WU
OAW-42 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTR2LkK2OFMh|ryP MnTyV2FPT0WU
C8166 NXnENnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTR3LkC4NlIh|ryP MWDTRW5ITVJ?
LU-99A MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HZNWlEPTB;NE[uNVMzOiEQvF2= NHrrZYdUSU6JRWK=
NCI-H23 NEDQNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTR4LkG3PFUh|ryP M2PUUnNCVkeHUh?=
HO-1-N-1 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDOVplKSzVyPUS3MlA6QThizszN M1HvPHNCVkeHUh?=
A3-KAW NUXsWHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\5O2lEPTB;NEeuNVAxPyEQvF2= NVjIV4lGW0GQR1XS
CGTH-W-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTR5LkWwOlkh|ryP NHG2cFFUSU6JRWK=
DJM-1 M{f0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LXb2lEPTB;NEeuOVQyOyEQvF2= M4DYb3NCVkeHUh?=
A101D Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LlUGlEPTB;NEeuOlM2PyEQvF2= MULTRW5ITVJ?
BB30-HNC MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{mybmlEPTB;NEiuN|A4OiEQvF2= M1K3RXNCVkeHUh?=
T98G MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPTTWM2OD12OD60OlM{KM7:TR?= Ml3YV2FPT0WU
NCI-H1573 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ixS2lEPTB;NEmuOFQ3OiEQvF2= NXGy[Xh4W0GQR1XS
MEG-01 NIXxOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjMTnlKSzVyPUS5Mlc1OTFizszN NELEUXFUSU6JRWK=
WM-115 NXjieVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK1O5NYUUN3ME20PU46OjJ{IN88US=> MYPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
DR5/CHOP; 

PubMed: 25531448     


(A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5.

γH2AX/H2AX; 

PubMed: 22933245     


FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX.

pATM; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

53BP1; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

NF-kB; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

pS6/S6; 

PubMed: 24831086     


HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies. 

25531448 22933245 27686740 24831086
Immunofluorescence
DNA damage; 

PubMed: 27686740     


(A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX).

γH2AX; 

PubMed: 28069876     


Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.

27686740 28069876
Growth inhibition assay
Cell viability ; 

PubMed: 25531448     


A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.

25531448
ELISA
IL-8; 

PubMed: 28456021     


ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. 

GLP-1; 

PubMed: 29392078     


Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.

28456021 29392078
In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

- Collapse

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

- Collapse
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms Ku-0059436
Smiles C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04515836 Not yet recruiting Drug: Olaparib Mesothelioma|Homologous Recombination Deficiency University of Chicago|AstraZeneca October 15 2020 Phase 2
NCT04024254 Recruiting Drug: Folic Acid Tablet Ovarian Cancer|Breast Cancer|Folic Acid Deficiency Rush University Medical Center July 21 2020 Phase 2|Phase 3
NCT04298021 Recruiting Drug: AZD6738|Drug: Durvalumab|Drug: Olaparib Bile Duct Cancer|Chemotherapy Effect Seoul National University Hospital June 25 2020 Phase 2
NCT04330040 Recruiting Drug: Olaparib Ovarian Cancer|Breast Cancer AstraZeneca May 30 2020 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • Answer:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • Question 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281) | Olaparib (AZD2281) supplier | purchase Olaparib (AZD2281) | Olaparib (AZD2281) cost | Olaparib (AZD2281) manufacturer | order Olaparib (AZD2281) | Olaparib (AZD2281) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID